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Background: Fetal exposure to a maternal low protein diet during rat pregnancy is associated with hypertension, renal
dysfunction and metabolic disturbance in adult life. These effects are present when dietary manipulations target only the
first half of pregnancy. It was hypothesised that early gestation protein restriction would impact upon placental gene
expression and that this may give clues to the mechanism which links maternal diet to later consequences.
Methods: Pregnant rats were fed control or a low protein diet from conception to day 13 gestation. Placentas were
collected and RNA sequencing performed using the Illumina platform.
Results: Protein restriction down-regulated 67 genes and up-regulated 24 genes in the placenta. Ingenuity pathway
analysis showed significant enrichment in pathways related to cholesterol and lipoprotein transport and metabolism,
including atherosclerosis signalling, clathrin-mediated endocytosis, LXR/RXR and FXR/RXR activation. Genes at the centre
of these processes included the apolipoproteins ApoB, ApoA2 and ApoC2, microsomal triglyceride transfer protein
(Mttp), the clathrin-endocytosis receptor cubilin, the transcription factor retinol binding protein 4 (Rbp4) and
transerythrin (Ttr; a retinol and thyroid hormone transporter). Real-time PCR measurements largely confirmed the
findings of RNASeq and indicated that the impact of protein restriction was often striking (cubilin up-regulated 32-fold,
apoC2 up-regulated 17.6-fold). The findings show that gene expression in specific pathways is modulated by maternal
protein restriction in the day-13 rat placenta.
Conclusions: Changes in cholesterol transport may contribute to altered tissue development in the fetus and hence
programme risk of disease in later life.
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The causes of chronic diseases of adulthood are com-
plex. In addition to influences of adult lifestyle, such as
dietary pattern, physical activity and the consumption
of alcohol and smoking, the environment experienced
during infancy and fetal life plays a critical role in estab-
lishing adult metabolic and cardiovascular phenotypes [1].
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and metabolic disorders that emerge later in life may
therefore already in place even before birth. Epidemio-
logical studies which show relationships between proxy
markers of poor nutrition in pregnancy and diseases
including cardiovascular disease, type-2 diabetes and
chronic kidney disease are supported by observations in
animals [2, 4–6]. Manipulating either overall food supply
or dietary composition such that one or more nutrients is
limiting during pregnancy leads to permanent changes in
organ structure and establishes a predisposition to ageing-
related insulin resistance, cardiovascular dysfunction and
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rat fetus to maternal undernutrition (both protein restric-
tion and iron deficiency) up to day 13 gestation (full-term
is 22 days) induced changes in renal morphology that may
underpin the development of hypertension in later life [7].
These effects were associated with a number of changes in
the expression of genes and proteins in the day 13 embryo,
which were clustered around regulation of the cell cycle,
the cytoskeleton and formation of clathrin vesicles [7, 8].
Whilst these processes within the embryo can be envisaged
as contributing to remodelling of tissues and therefore per-
manent changes in the physiology of the animal, leading to
later disease [9], they do not give an indication of what ini-
tiates these changes in response to maternal diet.
The placenta has long been recognised as having an im-
portant role in nutritional programming of later disease [10]
either through dietary modulation of placentally derived
hormones, dietary modulation of the placental transport of
hormones [11] or variation in the delivery of key substrates
to the developing fetus [12]. As such, it may be at the centre
of the response to maternal undernutrition and the transfer
of signals of adverse conditions from mother to fetus. Pla-
cental functions will vary with stage of development and the
demands of the fetus. In this study, we have focused on the
day-13 rat placenta. At this point, full development of the
organ has not been completed, but all five basic placental
layers are in place (myometrium, deciduum, giant tropho-
blasts, trophospongium and labyrinth; [13]. The tissue is rich
in blood cells and glycogen cells but has not yet developed
invasive vessels [13]. In the rat, maximum placental weight
is not reached until day 16. We hypothesised that the estab-
lished but immature placenta would show differential pat-
terns of gene expression in response to maternal protein
restriction. These patterns may give important clues as to
how maternal nutrition at this stage of development may
have long-term consequences for the fetus.
Methods
This paper reports data from analysis of placentas col-
lected in our previously published study of gene and pro-
tein expression in day-13 rat embryos [7]. Female virgin
Wistar rats (Harlan, UK) were subjected to a 12 h light
(08:00–20:00)-dark (20:00–08:00) cycle at a temperature
of 20–22 °C with ad libitum access to food and water. At a
weight of approximately 180–200 g, females were mated
with stud males. After conception, determined by the
presence of a semen plug on the cage floor, females were
single-housed and animals were fed either a control 18 %
(w/w) casein protein diet (control protein (CP)) or a 9 %
(w/w) casein (low protein (LP)) diet until day 13 gestation
(n = 8 per group). The LP diet was isocaloric relative to
the control (see Additional file 1: Table S1 for composition
of diets). To achieve a 50 % reduction in protein content
of the LP diet, an additional 9 % carbohydrate was added.We have previously discussed the relative contributions
of protein, carbohydrate and lipids to programming ef-
fects of the diet in detail [14–16]. During pregnancy,
the animals were weighed and food intake was recorded
daily. All animal work was performed under licence
from the Home Office (UK) and complied with the
Animals (Scientific Procedures) Act (1986). The project
was approved by the University of Nottingham, Animal
Ethics Committee.
On day 13 of gestation the rats were culled by CO2
asphyxia and cervical dislocation. Individual embryos
and placentas were harvested. Tails were removed from
embryos to establish sex. Tissues were snap frozen in
liquid nitrogen and stored at −80 °C. PCR was used to
verify presence or absence of the sex determining
region-Y (SRY) gene in lysed embryo tail tissue [7]. This
study used placenta only from male embryos and to
generate the RNA samples for RNASeq analysis three
placentas from the same litter were pooled. Only male
embryos were selected to remove complications of sex
from the analysis. Previous work has shown that the im-
pact of maternal undernutrition upon long-term health
of offspring is greater in males than in females [17–19].
Overall six samples per group were used for the analysis,
with each sample representing three placentas associated
with male embryos from a separate litter (18 placentas,
6 litters per group).
High-quality RNA was prepared from frozen tissue
using Roche High Pure Tissue Kit according to the
manufacturer’s instructions. Samples of high-quality
RNA (RIN >6.0) were sent to Oxford Gene Technology
(Begbrooke, Oxfordshire, UK) for polyA-enriched RNA
sequencing using the Illumina TruSeq RNA sample
prep kit v2 (Illumina, Little Chesterford, Essex, UK).
With this kit, total RNA was captured using olido-dT
coated magnetic beads and messenger RNA (mRNA)
was fragmented and randomly primed. First strand
complementary DNA (cDNA) was initiated from ran-
dom primers, followed by second strand synthesis.
After end repair, phosphorylation and A-tailing, adapter
ligation and PCR amplification was performed to pre-
pare the library for sequencing.
Sequencing was performed on the Illumina HiSeq2000
platform using TruSeq v3 chemistry. Read files (Fastq)
were generated from the sequencing platform via the
manufacturer’s proprietary software, and read level QC
metrics were generated by FastQC http://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc/). Reads were proc-
essed through the Tuxedo suite [20] and mapped to their
location using Bowtie version 2.o2 (http://bowtie-bio.
sourceforge.net/index.shtml). Cufflinks v2.1.1 (http://
cole-trapnell-lab.github.io/cufflinks/) was used to perform
transcript assembly, abundance estimation and differential
expression for the samples. RNASeq alignment metrics
Table 1 Differentially expressed genes in rat placenta at d13 gestation
Gene ID Locus Expression (control) Expression (LP) Fold−change (log2) Q value
Actg2 4:117732482-117747006 71.49 2.48 −4.85 0.00922
Gzmf 15:34696237-34707618 103.92 4.98 −4.38 0.00922
Gzmb 15:35195449-35198468 384.48 20.68 −4.22 0.00922
Nkg7 1:93813122-93814188 146.90 8.65 −4.09 0.00922
Prf1 20:28658366-28663866 171.89 10.39 −4.05 0.00922
Ccl5 10:71605790-71610330 59.82 4.15 −3.85 0.00922
Zbtb32 1:85635283-85637589 7.78 0.57 −3.77 0.04862
Asb2 6:127609501-127645492 5.26 0.46 −3.53 0.00922
Lama2 1:18203478-18885460 4.48 0.40 −3.49 0.00922
Cd96 11:56183624-56258356 11.16 1.03 −3.43 0.01702
MYH11_RAT 10:666714-776052 8.22 0.77 −3.42 0.00922
Rgs1 13:58121190-58125514 12.73 1.29 −3.31 0.00922
Ptprcap 1:206738734-206740893 13.28 1.57 −3.08 0.04148
LOC305103 13:88606173-88611105 120.74 14.38 −3.07 0.00922
D4ADB8_RAT 8:21210583-21221026 9.83 1.18 −3.06 0.00922
Cdh17 5:26047159-26099164 3.75 0.46 −3.02 0.02304
E9PSV0_RAT 20:4300723-4315876 10.67 1.34 −2.99 0.00922
Igfbp6 7:140885375-140890043 228.66 28.85 −2.99 0.00922
Col6a6 8:110793848-110892578 5.48 0.69 −2.98 0.00922
ADH1_RAT 2:235799456-235811584 69.42 9.27 −2.90 0.00922
Mcpt9 15:34541881-34544835 26.43 3.53 −2.90 0.00922
Lck 5:148707506-148718296 15.93 2.21 −2.85 0.00922
C1s 4:160736132-160748150 22.95 3.25 −2.82 0.00922
Pla1a 11:64099836-64137355 12.63 1.79 −2.82 0.00922
Sep1 1:186474714-186478580 11.10 1.58 −2.82 0.00922
COBA1_RAT 2:209996818-210193378 12.61 1.92 −2.71 0.02304
C1r 4:160712581-160729361 29.45 4.56 −2.69 0.00922
Q3MIE5_RAT 10:19207498-19660353 2.64 0.41 −2.67 0.00922
CLM8_RAT 10:104775859-104788927 15.09 2.50 −2.59 0.01702
Phf11 15:38444406-38477945 27.05 4.56 −2.57 0.00922
Sfrp4 17:53121424-53131513 42.94 7.23 −2.57 0.00922
Cytip 3:39893892-39921114 6.66 1.17 −2.50 0.02304
Rac2 7:116520065-116532482 38.51 6.90 −2.48 0.00922
C1qb 5:155647525-155653074 13.93 2.52 −2.47 0.02873
Coro1a 1:185852741-185857715 40.30 7.80 −2.37 0.00922
Aldh1a2 8:75692098-75771159 6.41 1.26 −2.35 0.00922
Pla2g2a 5:157654785-157657360 19.90 3.90 −2.35 0.02304
Smoc2 1:53165791-53295122 3.31 0.68 −2.29 0.04862
Rab27a 8:77798829-77861089 8.05 1.73 −2.22 0.00922
Serping1 3:67968807-67978102 39.91 8.61 −2.21 0.00922
D3ZXA0_RAT 15:38372728-38391822 21.10 4.62 −2.19 0.00922
RGD1565772 1:67630583-67648373 4.21 0.94 −2.17 0.00922
Rgs2 13:57890948-57894465 30.51 6.87 −2.15 0.00922
Psmb8 20:4786263-4789173 43.92 10.48 −2.07 0.00922
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Table 1 Differentially expressed genes in rat placenta at d13 gestation (Continued)
Tagln 8:48902208-48907693 99.68 23.75 −2.07 0.00922
C1qc 5:155656104-155659430 13.41 3.31 −2.02 0.04502
Prelp 13:46801474-46943977 12.67 3.13 −2.02 0.00922
LOC100365668 10:38109857-38110205 120.96 30.50 −1.99 0.00922
Fst 2:46542245-46550678 60.50 15.49 −1.97 0.00922
Ptprc 13:51246163-51357995 11.13 2.93 −1.93 0.00922
Selplg 12:43842267-43843560 11.84 3.10 −1.93 0.04862
Angpt4 3:142249114-142282307 14.42 4.07 −1.82 0.04502
Itgal 1:186561794-186598905 4.37 1.26 −1.80 0.02873
Fcer1g 13:87119465-87123902 78.98 23.70 −1.74 0.00922
Plek 14:97841598-97875052 18.70 5.63 −1.73 0.00922
Ccdc88b 1:209520223-209536201 3.50 1.06 −1.72 0.04502
Ifitm3 1:201198666-201199807 153.46 48.97 −1.65 0.01702
Pcolce 12:19672504-19678821 53.84 18.12 −1.57 0.04862
Plcg2 19:47875571-47947573 5.87 2.12 −1.47 0.03500
Prl8a7 17:44148436-44154238 43.87 15.87 −1.47 0.00922
Bgn X:159380548-159391521 29.57 11.81 −1.32 0.02873
Cgm4 1:77441012-77453814 15.02 6.04 −1.31 0.02304
Pmp22 10:49305834-49335864 30.24 12.39 −1.29 0.03500
Laptm5 5:149775895-149797951 70.71 29.18 −1.28 0.02304
Mmp12 8:4249934-4328865 53.39 26.46 −1.01 0.04502
Ifitm2 1:201134356-201135537 141.63 72.01 −0.98 0.02873
Prl7b1 17:43783361-43791538 96.93 51.16 −0.92 0.04502
Sod3 14:63381447-63387180 7.22 20.37 1.50 0.00922
Tf 8:108196748-108244545 62.61 188.51 1.59 0.02304
Gpc3 X:139192114-139393977 9.56 30.69 1.68 0.00922
Ccdc37 4:124661801-124671607 5.76 18.58 1.69 0.00922
Cldn2 X:127538684-127549018 1.66 5.37 1.69 0.04862
Pcdh24 17:15937976-15962796 1.80 6.02 1.74 0.02873
Muc13 11:68772164-68794880 3.41 11.77 1.79 0.00922
Fgg 2:174727311-174734592 11.29 41.76 1.89 0.00922
Creb3l3 7:10106524-10114955 3.23 12.04 1.90 0.01702
Mttp 2:235613709-235654848 2.33 9.12 1.97 0.00922
Serpinf2 10:62748115-62756200 3.56 14.05 1.98 0.00922
Serpina1 6:127998618-128021719 4.90 20.49 2.06 0.01702
Fmo1 13:78503769-78536359 6.70 28.40 2.08 0.00922
Maob X:17553528-17657839 6.15 26.17 2.09 0.00922
Rbp4 1:242443797-242450998 83.56 362.99 2.12 0.00922
Tdh 15:42758307-42771849 4.69 21.22 2.18 0.00922
Ttr 18:12406550-12413680 135.68 616.60 2.18 0.00922
Vil1 9:73748631-73776345 1.11 5.07 2.19 0.04502
Apoa4 8:49233139-49233436 61.26 291.64 2.25 0.00922
Apob 6:31508011-31556597 9.20 43.86 2.25 0.00922
Apoa2 13:87114733-87116372 70.35 335.96 2.26 0.00922
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Table 1 Differentially expressed genes in rat placenta at d13 gestation (Continued)
Spp2 9:87297051-87316545 16.85 80.97 2.26 0.00922
Apoc2 1:78979033-78980136 42.59 241.21 2.50 0.00922
Cubn 17:87655812-87772079 0.96 6.33 2.72 0.00922
n = 6 per group
Table 2 Pathways significantly influenced by maternal protein
restriction in the day 13 rat placenta
Pathway P value
(log10)
Differentially expressed
genes in pathway
Acute-phase signalling 11 C1R, C4A/C4B, Serpin G1,
TTr, TF, C1S, ApoA2, Serpin
A1, Serpin F2, Fgg, Rbp4
FXR/RXR activation 10.9 C4A/C4B, TTr, ApoB, TF,
ApoA2, Serpin A1, ApoC2,
Serpoin G2, Mttp, Rbp4
LXR/RXR activation 9.59 C4A/C4B, Ttr, ApoB, TF,
ApoA2, ApoC2, Serpin A1,
Serpin F, Rbp4
Atherosclerosis signalling 6.72 ApoB, ApoA2, ApocC2,
Serpin A1, Pla2g2A, Selpg,
Rbp4
Clathrin-mediated endocytosis 5.55 ApoB, RF, ApoA2, ApoC2,
Serpin A1, Actg2, Rbp4
IL12 signalling in macrophages 4.08 ApoB, ApoA2, ApoC2,
Serpin A1, Rbp4
Coagulation system 3.66 Serpin A1 Serpin F2, Fgg
Nitric oxide and ROS
production in macrophages
3.47 ApoB, ApoA2, ApoC2,
Serpin A1, Rbp4
The table shows ingenuity canonical pathways with significant enrichment in
comparison of control and low protein exposed placentas
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github.io/picard/).
RNASeq was carried out on 12 samples with an aver-
age of 12279507 paired end reads per sample. A total of
11.63 gigabases of sequence data were read and aligned
at high quality. The number of mapped reads per sample
ranged from 3081828 to 17579532, and the proportion
of mapped reads exceeded 99 % across all samples. The
percentage of high-quality aligned bases was in excess of
98.5 and >96.5 % of reads were aligned in pairs.
Data was analysed using Cufflinks v2.1.1. A one-sided
t test was used to determine the significant changes in
gene expression (P value), and a Benjamini-Hochberg
correction for multiple testing was also used (q value) as
reported by Trapnell et al. [21]. Selection of genes iden-
tified as differentially expressed in the protein restricted
group was based upon false discovery rate adjusted q
values <0.05 (unadjusted P < 0.0005). Pathways and net-
works of interacting proteins enriched for differentially
expressed genes were identified using ingenuity pathway
analysis. Statistical enrichment is calculated by a right
tailed Fisher’s exact test (IPA, QIAGEN Redwood City
www.qiagen.com/ingenuity).
To further explore the differential expression data, we
performed quantitative real-time PCR for 13 genes that
were differentially expressed according to the RNASeq
analysis. These included seven genes in the main pathways
showing enrichment in the ingenuity analysis (ApoA2,
ApoC2, Ttr, Fgg, Actg2, serpin G1 and Rbp4); Cubn and
Mttp, which have functions closely related to those
enriched pathways; and four genes that were shown to be
differentially expressed in the protein restricted condition
(Vil1, Gpc3, Muc13, Prf1). The PCR measurements were
performed on the same RNA samples that were originally
analysed through RNASeq. Total RNA (500 ng) was re-
verse transcribed using a cDNA synthesis kit (RevertAid
RT Reverse Transcription Kit, Thermo Fisher) with ran-
dom primers. Real-time PCR primers were designed using
Primer Express software (version 1.5; Applied Biosystems)
from the RNA sequence, checked using BLAST (National
Center for Biotechnology Information) and were pur-
chased from Sigma (UK). The primer sequences for these
analyses are presented in Additional file 2: Table S2. Real-
time PCR was performed on a Lightcycler 480 (Roche,
Burgess Hill, UK) using the 384 well format. Each reaction
contained 5 μl of cDNA with the following reagents: 7.5 μl
SYBR green master mix (Roche), 0.45 μl forward andreverse primers (final concentration 0.3 μM each) and
1.6 μl RNase-free H2O. Samples were pre-incubated at
95 C for 5 min followed by 45 PCR amplification cycles
(de-naturation, 95 C for 10 s; annealing, 60 C for 15 s;
elongation, 72 C for 15 s). Transcript abundance was
determined using a standard curve generated from serial
dilutions of a pool of cDNA made from all samples. Ex-
pression was normalised against the expression of
cyclophilin, which was shown to be unaffected by ma-
ternal diet in the RNASeq analysis and subsequently by
PCR. The primer sequences for these analyses are
presented in Additional file 2: Table S2. Data from real-
time PCR measurements was tested using independent
samples t tests. Ten of the targets were shown to be
differentially expressed in the protein restricted group,
confirming the RNASeq analysis.
Results
The RNASeq analysis revealed differential expression
of 91 genes in the day 13 rat placenta in response to
maternal protein restriction. Of these, 24 were up-
regulated and 67 were down-regulated. The full list of
differentially expressed genes is provided in Table 1, and
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file 3: Table S3.
Analysis of the data set using ingenuity pathway
analysis identified 19 pathways that were significantly
affected by maternal protein restriction with P < 0.01. A
more stringent cut-off of P < 0.001 identified eight
significantly affected pathways (Table 2). The top six
pathways (acute-phase response signalling, FXR/RXR
activation, liver X receptor (LXR)/retinoid X receptor
(RXR) activation, complement system, atherosclerosis
signalling, clathrin-mediated endocytosis signalling)
were closely related functionally, with a strong focus on
cholesterol uptake and efflux across the placenta.
Figure 1 shows heat maps for the genes involved in the
functionally interesting enriched pathways. A relativelyFig. 1 Heatmaps of gene expression (log2 FPKM) for pathways that are sig
signalling. b Clathrin-mediated endocytosis. c LXR/RXR activation. D FXR/RXsmall number of genes contributed to the enrichment
noted for all of these pathways (Ttr, ApoA2, ApoB,
ApoC2, Fgg, Rbp4, Serpin A1, Serpin F2 and Serpin G1).
To validate the observations made using RNASeq
analysis, quantitative real-time PCR was performed to
explore the expression of 13 genes in two selection
groups. The first group comprised genes that were
differentially expressed with protein restriction and
deemed functionally significant (associated with choles-
terol transport) based upon the Ingenuity analysis (Ttr,
ApoA2, ApoC2, Rbp4, Fgg, Actg2). The second group
were genes that were differentially expressed but not
associated with the pathways identified by Ingenuity
(Muc13, Vil1, Gpc3, Cubn, Mttp). It should be noted
that Cubn has a role in the uptake of high-densitynificantly influenced by maternal protein restriction. a Atherosclerosis
R activation
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Mttp has a role in the packaging of cholesterol and
lipid into low-density lipoprotein (LDL). Figures 2 and
3 show the data from the PCR analyses of these genes
and Table 3 compares the fold-change in expression
noted in the RNASeq analysis. The majority of genes in
the validation set were strongly over-expressed in pla-
centas from protein restricted pregnancies compared to
controls, with a minimum of 4.53-fold (Gpc3) and max-
imum 41.35-fold (Fgg) up-regulation noted in this set.
PCR analysis of three genes did not reproduce the sta-
tistically significant effects of protein restriction thatFig. 2 Expression of genes related to enriched pathways. Real-time qualita
related to canonical pathways identified by ingenuity as significantly influe
cyclophilin mRNA expression and *P < 0.05 between groups. n = 6 per grouwere shown by RNASeq (Actg2, SerpinG1 and Prf1;
Fig. 4). The PCR analysis generally detected a greater
degree of up-regulation in the validation set than was
noted with RNASeq (Table 3).
Discussion
In this experiment, we tested the hypothesis that mater-
nal protein restriction would impact upon gene expres-
sion in the day-13 rat placenta. The data showed that
this was in fact the case and that although the number
of genes affected was small, the nutritional insult had a
major impact upon expression of genes associated withtive PCR was used to validate the differential expression of seven genes
nced by maternal protein restriction. Expression was normalised to
p
Fig. 3 Expression of genes unrelated to enriched pathways. Real-time qualitative PCR was used to validate the differential expression of six genes
related to canonical pathways identified by ingenuity as significantly influenced by maternal protein restriction. Expression was normalised to
cyclophilin mRNA expression. *P < 0.05 between groups. n = 6 per group
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expression of genes involved in the uptake of cholesterol
by the placenta from HDL- LDL- and very low-density
lipoprotein (VLDL)-cholesterol (ApoA2, ApoB, ApoC2,
Cubn), the formation of clathrin-coated pits in which
VLDL- and LDL-cholesterol receptors are located (Tf,
Orm1, ApoA2, ApoC2, Actg2, Rbp4), the regulation of
cholesterol efflux (Ttr, Tf, Orm1, Serpin F1, Rbp4, Mttp,
Fgg, Serpin F2, Serpin A1) and the efflux from the
placenta as LDL-cholesterol (ApoB, Mttp) were generally
up-regulated by maternal undernutrition. Importantly,
we have confirmed that the effects of maternal protein
restriction during the first half of pregnancy may be me-
diated through changes in placental function.Previous studies suggest that placental structure and
organisation may be influenced by maternal protein re-
striction in both rats and mice [22–24]. These diet-
related changes appear to be related to differential
expression of adhesion molecules (beta catenin and
vascular endothelial cadherin) and impaired cell prolif-
eration. These processes appeared to be largely un-
affected in the present study (although cadherin Cdh17
was down-regulated by protein restriction) and the
discrepancies may stem from species differences or dif-
ferences in stage of gestation at which samples were
collected.
Functionally, placentas from protein-restricted rodents
are known to differ in terms of materno-fetal steroid
Table 3 Comparison of fold-change in gene expression between
RNASeq and real-time PCR
Gene Log2 fold-change RNA Seq Log2 fold-change RNA PCR
Actg2 −4.85*** 0.28
Apo A2 2.26*** 4.79*
Apo C2 2.52*** 4.14*
Cubn 2.71*** 5.01*
Fgg 1.88*** 5.37*
Gpc3 1.68*** 2.18*
Mttp 1.97*** 3.14*
Muc13 1.79*** 2.71*
Prf1 −4.04*** 1.68
Rbp4 2.11*** 3.85*
Serpin G1 −2.21*** 0.69
Ttr 2.18*** 3.52*
Vil1 2.19*** 3.41*
Significant differences were noted between control and low protein exposed
placentas within each analytical approach (*P < 0.05, ***P < 0.001)
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acids [12, 25, 26]. Whilst specific genes related to these
functions have been previously identified as being sensi-
tive to protein restriction, none were found to be differ-
entially expressed in the current study. This is most
likely explained by our study concentrating on day-13
rather than later stage placentas.
Cholesterol transport across the placenta is complex
and involves a large number of proteins [27]. Choles-
terol reaches the placenta in the form of LDL- VLDL-
and HDL-cholesterol, which have ApoB, ApoC2 and
ApoA2 respectively as their key structural proteins.
LDL- and VLDL-cholesterol are taken up by their re-
spective receptors which are located in clathrin-coated
pits on trophoblasts. HDL-cholesterol can be taken up
by SR-B1 (scavenger receptor class B member 1) or by
binding to proteins such as megalin and cubilin. The
latter two are multifunctional receptors which mediate
uptake of material by endocytosis [28, 29]. Once taken
up by trophoblasts, cholesterol is hydrolysed to chol-
esterol esters. Export from trophoblasts is in the form
of either LDL-cholesterol or HDL-cholesterol. LDL-
cholesterol is formed through placental expression of
apoB and the action of microsomal triglyceride transfer
protein (Mttp). HDL-cholesterol can be formed through
complexing of lipids and cholesterol with a range of
different apolipoproteins (ApoA1, ApoE, ApoA4, ApoC1,
ApoC4; [27]). These are synthesised in response to
LXR/RXR activation [30]. ApoA1 synthesis is also
influenced by FXR/RXR activation [31]. Cholesterol
efflux for formation of HDL-cholesterol complexes is
dependent upon a range of ATP binding cassette proteins(AbcA1, AbcG1, AbcG5, AbcG8, [27]), which are down-
stream targets of FXR/RXR activation [32]. The present
study has shown that almost all of these processes
are sensitive to maternal protein restriction, and im-
portantly, we have found that the only significant
enrichment of pathways within our dataset lies in
these processes. If there are any strong drivers of
nutritional programming through the placenta at this
stage of development, then cholesterol must play a
key role.
The uptake of cholesterol by the embryo and fetus is
critical for normal development [27], and defects of
endogenous cholesterol synthesis are known to be le-
thal [33]. Cholesterol will also play an important role
in placental function as it is the precursor for all
steroid hormone synthesis. Disturbances of placental
transport or endogenous fetal synthesis can have a
number of effects on growth, cell proliferation, metab-
olism and the organisation of tissues [27, 34]. Low ma-
ternal cholesterol is associated with lower birth weight
and microcephaly in humans [35], and women who
have growth retarded infants have been found to have
lower circulating cholesterol [36]. Optimal cholesterol
transport to the fetus is therefore likely to have a posi-
tive impact upon development, and it is known that
some of the effects are mediated through the cell cycle
[37, 38]. However, some animal studies suggest that ex-
cessive cholesterol may also have a negative impact on
growth. Bhasin et al. [39] reported that hypercholester-
olaemia in pregnant LDL receptor knockout mice was
associated with intrauterine growth retardation. The
relationship between fetal cholesterol and the normal
development and organisation of tissues may therefore
be complex.
It is known that hypercholesterolaemia during preg-
nancy is associated with adverse health outcomes in
the longer term. In humans, there is evidence that ma-
ternal hypercholesterolaemia is associated with the
development of fatty streaks in fetal arteries [40], and
cholestasis during pregnancy is associated with pro-
gramming of an overweight, insulin-resistant pheno-
type in humans [41]. Animal studies have shown
greater atherosclerosis in offspring of hypercholester-
olaemic mothers [42, 43]. Previous work from our la-
boratory showed that in the ApoE*3 Leiden mouse, a
transgenic rodent which has a predisposition to athero-
sclerosis, maternal protein restriction during fetal devel-
opment increased atherosclerotic lesion size in adult
life [44]. As atherosclerosis in this mouse is related to
the degree of cholesterol exposure, it may be that intra-
uterine exposure to higher than normal cholesterol
transport across the placenta may contribute to the
adult disease phenotype. Induction of cholestasis using
cholic acid in mouse pregnancy produces the same
Fig. 4 PCR analysis of three genes
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with greater cholesterol efflux from the placenta.
This study was an initial exploratory study to estab-
lish whether the placental transcriptome was signifi-
cantly impacted by maternal protein restriction and to
determine whether any observed effects were isolated
to discrete processes within the tissue. One limitation
of the study is that the whole placenta was used to
generate the RNA, with no distinction between the
maternal and fetal placental tissue. In the absence of
any direct measurements of cholesterol transport or
measurement of the genes of interest at the level of
protein, assumptions are being made about the pro-
cesses of cholesterol uptake and efflux being sensitive
to maternal undernutrition. These measurements will
be a priority for future studies, as will confirmation
that placentas associated with female embryos respond
in the same way as those from males.Conclusions
Current thinking about the mechanisms which link ma-
ternal nutritional status and long-term health in off-
spring is largely focused upon lasting epigenetic changes
within the fetal genome [45]. This study has highlighted
placental function as being modulated by maternal un-
dernutrition and reinforces the alternative concept that
programming of fetal development and long-term health
may be a product of dysregulation of nutrient transfer
across the placenta. Further studies are needed to evalu-
ate cholesterol transport across the placenta in protein-
restricted pregnancies and to determine the impact of
cholesterol on fetal gene expression, epigenetic regulation
of gene expression and tissue morphology. This analysis of
the placental transcriptome at the point where the pla-
centa is not fully mature has supported the hypothesis that
maternal undernutrition impacts upon placental function.
The findings of this study will provide a platform for
Daniel et al. Genes & Nutrition  (2016) 11:27 Page 11 of 12further investigation of processes within placenta that may
be important new mechanistic targets or biomarkers that
indicate nutritional programming of disease.
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